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Retinal pathologies are frequently accompanied by retinal
vascular responses, including the formation of new ves-
sels by angiogenesis (neovascularization). Pathological
vascular changes may also include less well characterized
traits of vascular remodeling that are non-neovascular,
such as vessel pruning and the emergence of dilated and
tortuous vessel phenotypes (telangiectasis). Themolecular
mechanisms underlying neovascular growth versus non-
neovascular remodeling are poorly understood.We there-
fore undertook to identify novel regulators of non-neovas-
cular remodeling in the retina by using the dystrophic
Royal College of Surgeons (RCS) rat and the retinal dystro-
phy 1 (RD1) mouse, both of which display pronounced
non-neovascular remodeling. Gene expression profiling
of isolated retinal vessels from these mutant rodent mod-
els and wild-type controls revealed 60 differentially ex-
pressed genes. These included the genes for apelin (Apln)
and for its receptor (Aplnr), both of which were strongly
up-regulated in the mutants. Crossing RD1 mice into an
Apln-null backgroundsubstantially reducedvascular telan-
giectasia. In contrast, Apln gene deletion had no effect in
two models of neovascular pathology [laser-induced cho-
roidal neovascularization and the very low density lipo-
protein receptor (Vldlr)-knockout mouse]. These findings
suggest that in these models apelin has minimal effect on
sprouting retinal angiogenesis, but contributes signifi-
cantly to pathogenic non-neovascular remodeling. (Am J
Pathol 2012, 180:399–409; DOI: 10.1016/j.ajpath.2011.09.035)
Development of the retinal vasculature is initiated by blood
vessels in the optic nerve head. These vessels form sprouts
that develop into a primitive vascular plexus by the processof angiogenesis.1 Initially, a simple network is established at
the inner surface of the retina; from there, vascular sprouts
subsequently penetrate the retina to form a second, deeper
plexus. To generate the patterned and hierarchically
branched network characteristic of the mature retinal vas-
culature, these primary vascular plexuses undergo exten-
sive remodeling to achieve the final vascular configuration.
Much research has focused on sprouting angiogenesis in
the retina because of its link to pathology in the adult (re-
ferred to as neovascularization), including blinding compli-
cations in diseases such as diabetic retinopathy or age-
related macular degeneration. Various trophic factors have
been identified as important regulators of the process. with
the vascular endothelial growth factors (VEGFs) and their
receptors being viewed as critical components.2 Indeed,
therapeutic targeting of VEGF in ocular angiogenesis has
resulted in improved clinical outcome in a number of sight-
threatening conditions. Nevertheless, other factors, includ-
ing transforming growth factor 1 (TGF-1), basic fibroblast
growth factor (bFGF), insulin-like growth factor 1 (IGF-1),
platelet-derived growth factor (PDGF), and angiopoietin are
also thought to contribute, either by modifying the VEGF
response or by independently regulating the remodeling of
existing vessels.
Non-neovascular remodeling is a characteristic of
many sight-threatening retinal diseases. For instance,
adult vessels can become telangiectatic (tortuous and
dilated) in diseases such as macular telangiectasia,3 di-
abetic retinopathy,4 Coats’ disease,5 radiation-induced
retinal telangiectasia,6 and ataxia-telangiectasia.7 Simi-
larly, in the retinitis pigmentosa (RP) family of diseases
the degeneration of photoreceptors leads to remodeling
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cally similar patterns of non-neovascular remodeling are
also observed in rodent models with photoreceptor de-
generation, such as the Royal College of Surgeons (RCS)
rat and the retinal degeneration 1 (RD1) mouse. In the
RCS rat, retinal degeneration occurs because of a muta-
tion in theMertk gene, resulting in defective phagocytosis
of the outer segments and photoreceptor cell death.9,10
The deeper plexus of the retinal vasculature subse-
quently becomes leaky and develops telangiectatic ves-
sels.11 In the RD1 mouse, rapid photoreceptor loss due
to the presence of a mutation within the photoreceptor
cGMP phosphodiesterase gene begins at postnatal day
8 (P8), with complete rod photoreceptor atrophy occur-
ring by 4 weeks of age.12,13 This mutation also results in
accompanying vascular atrophy. Vessels develop normally
up to P12, but loss of capillaries within the deep vascular
plexus follows, with subsequent appearance of telangiec-
tatic vessels.14,15 The remodeling of existing vessels, such
as the formation of telangiectasia, is clearly an important
phenomenon that contributes to pathogenesis in a number
of ocular and nonocular diseases. Although factors that
contribute to developmental remodeling have been identi-
fied,16 those responsible for driving non-neovascular patho-
genic modifications remain poorly defined.
In the present study, we investigated non-neovascular
remodeling in two rodent models with retinal degenera-
tive disease, the RCS rat and the RD1 mouse. Having
established that the vascular changes, including the de-
velopment of telangiectatic vessels, are non-neovascular
and anatomically similar in both models, we embarked on
gene expression analysis of isolated retinal microvascu-
lar fragments to identify candidate genes contributing to
the process. A group of differentially expressed genes
were identified, of which two [apelin (Apln) and its recep-
tor (Aplnr)] were investigated further to establish their
potential role in non-neovascular remodeling.
In the retina, Aplnr transcripts were uniquely expressed
by endothelial and/or associated mural cells, whereas
Apln was expressed predominantly by vessels but also
other cells of the retina. Analysis of Apln-knockout mice
revealed fewer radial veins and arteries and an increase
in arteriovenous crossover. Furthermore, during retinal
vascular development, radial veins failed to remodel into
deep drainage venules in the Apln-knockout mice. In RD1
mice lacking the apelin gene, there was a similar failure to
develop these deep drainage venules. Crucially, however,
there was also a significant reduction in pathogenic telan-
giectatic vessels arising in the intermediate vascular plexus.
These data indicate a key role for apelin in both develop-
mental and pathogenic non-neovascular remodeling.
Materials and Methods
Animals
RD1 mice12 and Vldlr/mice17 were purchased from the
Jackson Laboratory (Bar Harbor, ME). Control C57BL/6J
mice were purchased from Harlan Laboratories (Black-
thorn, UK). RCS dystrophic and congenic rats were bredfrom an established in-house colony; the Apln-knockout
mice were was a generous gift from Dr. J.M. Penninger,
Vienna, Austria.18 Double-mutant mice were generated
by crossing an Apln-knockout mouse with an RD1 mouse
to generate heterozygote offspring (R//A/). These
were crossed, and the resultant offspring were geno-
typed to identify animals that were both homozygous RD1
mutants and heterozygous Apln mutants (R//A/).
These mice were then crossed to generate RD1 homozy-
gous mutants that were also either homozygous wild type
for Apln (R//A/) or homozygous mutant for Apln
(R//A/). The same procedure was applied to gener-
ate double-Vldlr and Apln-knockout mice. All experiments
were performed in accordance with the Animals (Scien-
tific Procedures) Act and ethically approved by the UK
Home Office.
Vessel Isolation
Rat or mouse retinas were enzymatically digested in col-
lagenase/dispase (1 mg/mL; Roche, Welwyn, UK) and
DNase (20 U/mL; Ambion, Warrington, UK) at 37°C for 45
to 60 minutes. The microvessels were extracted using
either anti-mouse or anti-rat PECAM-1 antibodies (BD
Bioscience, Oxford, UK, and AbD Serotec, Kidlington,
UK, respectively), followed by either sheep anti-mouse or
sheep anti-rat IgG-conjugated magnetic beads (Dyna-
bead; Invitrogen, Paisley, UK) and magnetic separation.
The bead-bound vessels (vessel-enriched) and vessel-
depleted fractions were separately lysed for Western
blotting or for RNA extraction and analysis.
Immunohistochemistry
Bead-bound vessels were paraformaldehyde-fixed and
then dried onto SuperFrost microscope slides (VWR In-
ternational, Leicestershire, UK). They were then stained
with anti-collagen IV (AbD Serotec), caveolin 1 (BD
Biosciences), fibronectin (Millipore–Chemicon Interna-
tional, Temecula, CA), or -smooth muscle actin
(ASMA) (Sigma-Aldrich, Dorset, UK) antibodies, followed
by incubation with their respective Alexa Fluor 555- and
488-labeled secondary antibodies (Invitrogen).
Retinal whole mounts were fixed and stained as de-
scribed previously.1 Briefly, eyes were rapidly fixed in 2%
paraformaldehyde before retinal dissection in PBS and
refixation in 100% ice-cold methanol overnight at 20°C.
Retinas were rehydrated, blocked in blocking buffer (3%
Triton-X-100, 1% Tween-20, 0.5% bovine serum albumin
in PBS) and incubated overnight with either rabbit-anti-
mouse collagen IV (AbD Serotec) or fluorescein isothio-
cyanate-isolectin B4 (Vector Laboratories, Peterborough,
UK). Retinas were then washed before incubation with
Alexa Fluor 488-labeled secondary antibodies (Invitro-
gen) and mounted in Mowiol 4-88 reagent (Merck
Chemicals, Nottingham, UK) and examined by fluores-
cence (Leica) or confocal (Zeiss LSM 510) light micros-
copy. For quantification of telangiectatic vessels, the
number of 360-degree turns in the vessels were
counted per retina. For evaluating the vascular growths
in the Vldlr/ animals, the numbers of collagen IV-
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per retina and averaged.
Laser-Induced Choroidal Neovascularization
Laser-induced choroidal neovascularization (CNV) and
quantification using fundus fluorescein angiography was
performed as described previously.19 Three laser lesions
per eye were delivered at two to three disk diameters
away from the optic nerve head with a slit-lamp-mounted
diode laser system (Keeler SL-16, Windsor, UK; wave-
length: 680 nm; laser settings: 210 mW power, 100 ms
duration, 100 m spot diameter). At 2 weeks after laser
induction, in vivo fundus fluorescein angiography was
performed, and images from the early phase (90 seconds
after fluorescein injection) and late phase (7 minutes)
were obtained using a Kowa Genesis small animal fun-
dus camera with appropriate filters (Kowa Optimed, Tor-
rance, CA). The pixel area of CNV-associated hyperfluo-
rescence was quantified for each lesion using ImageJ
version 1.44i image analysis software (NIH, Bethesda,
MD). To quantify the volume of the CNV lesions, whole
mounts of the eye cup were prepared by carefully peel-
ing off the neural retina and exposing the CNV attached
to the retinal pigment epithelium (RPE). CNV lesions were
immunostained for PECAM-1 using the protocol de-
scribed above for immunohistochemistry. Confocal sec-
tions were obtained using a Zeiss LSM 710 upright con-
focal microscope using a 40 water immersion plan
Apochromat lens. Z-stacks were captured and three-di-
mensional images were reconstructed, followed by sur-
face rendering, using Imaris software version 7.3 (Bit-
plane, Zurich, Switzerland). CNV volume was calculated
using the Imaris measurement module.
SDS-PAGE and Western Blotting
Proteins were separated by SDS-PAGE, transferred onto
a nitrocellulose membrane by wet transfer, bovine serum
albumin blocked, and incubated with goat anti-VE-cad-
herin (Santa Cruz Biotechnology, Heidelberg, Germany),
followed by HRP-conjugated secondary antibodies
(Santa Cruz Biotechnology). Blots were developed using
luminescent substrates (Roche, Welwyn, UK). The gel
was subsequently stained using Coomassie Blue and
destained to visualize the bands. Densitometry was per-
formed using ImageJ software version 1.44i.
Quantitative Real-Time PCR
RNA was extracted using TRIzol reagent (Invitrogen),
followed by an RNeasy clean-up (Qiagen, West Sussex,
UK). RNA was DNase-treated and reverse-transcribed
using Qiagen QuantiTect kits, and real-time PCR was
performed using Power SYBR PCR master mix (Applied
Biosystems, Paisley, UK). The following primers were
used: mouse VE-cadherin (Fwd: 5=-CATAAACAACAAT-
GACAACACC-3=, Rev: 5=-GATGATCAGCAAGGTAAT-
CAC-3=); PDGFR- (Fwd 5=-TGTAGACTTGGAGAA-
TACTGC-3=, Rev: 5=-CGCTCTCACACACTTACC-3=) rho-
dopsin (Fwd: 5=-TGGTGGTCTGTTGCTCTC-3=, Rev: 5=-GCTGCTCTATCACATTCCC-3=); desmin (Fwd: 5=-TC-
ATCGCCCTTCCCCTTC-3=, Rev: 5=-GTCCACAAACTCG-
GTCCTG-3=) APLNR (Fwd: 5=-GGGAGTAAGTTTGGG-
AAAGAG-3=, Rev: 5=-TGGAATATGTCTTGTCCTTGG-
3=); APLN (Fwd: 5=-GGCCTTCTCCGTCTTTGTCG-3=, Rev:
5=-CCCTCTTGTGCTTCTATCTCTCC-3=); PECAM1 (Fwd:
5=-GCCAGTCACTTGAAGACAGACC-3=, Rev: 5=-TGGA-
ACGGAAAGGAAGATCAAGG-3=); -actin (Fwd: 5=-TCCA-
AGTATCCATGAAATAAGTGG-3=, Rev: 5=-GCAGTACATA-
ATTTACACAGAAGC-3=); VEGF (Fwd: 5=-GACTTGTG-
TTGGGAGGAGGA-3=,_Rev: 5=-TCTGGAAGTGAGCCAA-
TGTG-3=). Rat APLNR (Fwd: 5=-TTGGTCTCTTCTCTGTC-
AGGAC-3=, Rev: 5=-GTCACTCTTTCACAACCTTACCC-3=);
APLN (Fwd: 5=-CGTGTAGGGAGGTGAGTGCTTGTA-
TC-3=, Rev: 5=-CGAACAGATGCCAAAGGACTTAAAAG-
GG-3=); -actin (Fwd: 5=-ATCGTGCGTGACATTAAA-3=,
Rev: 5=-GCCACAGGATTCCATACC-3=); VEGF (Fwd: 5=-
GGTGACCAAGCACGGTGGTCC-3=, Rev: 5=-TAAGAA-
GGACGAAAGACCACACCGG-3=). Genotyping primers
were as follows: RD1 mutant20: 5=-GTAAACAGCAA-
GAGGCTTTATTGGGAAC-3=, RD1 wild-type: 5=-TACCCA-
CCCTTCCTAATTTTTCTCAGC-3=, RD1 common: 5=-TGA-
CAATTACTCCTTTTCCCTCAGTCTG-3=; APLN mutant: 5=-
GACAGTTTCTCTAACTCAAAGGGCC-3=, APLN wild type:
5=-GCTTCCTTCTTCTAGTCCTGTTCCA-3=, APLN common:
5=-ATGTCTGGGTGTAGGTCCATAAAGG-3= (MWG Bio-
tech, London, UK).
Microarrays
Microvessels were isolated from six nondystrophic and
six dystrophic RCS rat retinas, all rats at 5 months of age.
The RNA was extracted, amplified, and labeled for mi-
croarray analysis using an Affymetrix two-cycle labeling
kit according to the manufacturer’s instructions (Af-
fymetrix, High Wycombe, UK). Similarly, RNA was ex-
tracted from isolated vessels from 12 C57BL/6J mice (15
weeks of age) and 12 RD1 mice (18 weeks of age) and
processed for microarray analysis. This was repeated
four times for each animal model, providing RNA for four
chips per animal model. RNA quality was checked using
an Agilent Technologies (Santa Clara, CA; Waldbronn,
Germany) bioanalyzer before hybridization to Affymetrix
mouse 430.2 or rat 230.2 gene arrays at the UCL Wolfson
Institute and UCL Institute for Child Health Microarray
Facility. The data were analyzed using Bioconductor 2.0
and RGui software version 2.5.1 as described previ-
ously.21
Statistical Analysis
Paired and unpaired data were analyzed using a Stu-
dent’s t-test. A maximum P value of 0.05 was considered
significant. For the microarrays, statistical analysis was
done using the RGui LIMMA software package version
2.5.1 as described previously.21 A false discovery rate
statistical post hoc test (q  0.05) was used for the RD1
mouse, and a log2 fold change of 2 with a P value of
0.01 was used for the RCS rat.
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RCS Dystrophic Rats and RD1 Mice Display
Similar Vascular Remodeling
Detailed examination of the retinal vasculature of RCS
dystrophic rats and RD1 mice was performed to establish
the pattern of vascular remodeling in these animals. The
retinas were flat-mounted and examined by immunostain-
ing for collagen IV or isolectin B4. Compared with non-
dystrophic RCS rats (Figure 1, A and B), the dystrophic
RCS rat at 5 months of age had substantial retinal thin-
ning due to photoreceptor degeneration, as well as ex-
tensive vascular abnormalities across the outer retina
(Figure 1, C and D). Vessels from the deeper plexus had
remodeled into telangiectatic vascular complexes that fre-
quently consisted of length-expanded capillaries, folded in
Figure 1. Vascular remodeling in the RCS rat and the RD1 mouse. A and B:
Nondystrophic RCS rat (20 weeks of age). C and D: Dystrophic RCS rat (20
weeks of age). E and F: C57BL/6J mouse (15 weeks of age). G–K: RD1 mouse
(4.5 months). L and M: Vldlr/ mouse (16 weeks of age). Retinas were
flat-mounted, vessels stained for collagen IV (A–H and J–M) or isolectin B4
(I) and viewed from the outer retina. Arrowheads in G indicate a tortuous
vessel arising from the intermediate plexus (shown at higher magnification in
H). In J and K, a remodeled radial vein is shown (arrowheads), associated
with telangiectatic vessels (arrows). N: VEGF gene expression was mea-
sured in RCS rats, RD1 mice, and Vldlr/mice by qPCR, relative to congenic
RCS rats or C57BL/6J mice. Data are expressed as means SEM (n 3). *P
0.05; **P  0.01; ***P  0.001, Student’s t-test. Scale bars: 100 m (A, C, E, J,
and L); 50 m (G and M); 20 m (F, H, I, and K); 10 m (B and D).a corkscrew-like fashion. In some instances, these com-plexes were directly associated with the RPE. These obser-
vations are consistent with previous reports.11,22
In 4.5-month-old RD1 mice, we observed morpholog-
ically similar telangiectatic vessels extending from the
remaining neuroretina toward the subretinal space (Fig-
ure 1, G and H), which were absent in wild-type
C57BL/6J mice (Figure 1, E and F). Some of the telangi-
ectatic vascular remodeling occurred on capillaries from
the intermediate to deeper plexus (Figure 1, G and H)
and some on vessels linked to drainage veins in the
deeper plexus (Figure 1, J and K). Similar abnormalities
have been reported previously and are most probably the
precursors to RPE-associated vascular complexes ob-
served from 6 months of age.15 At the earlier time points
investigated, no association of vessels with the RPE was
observed. The telangiectatic vessels stained positively
for isolectin B4 (Figure 1I), demonstrating that they con-
tained viable endothelial cells and were not acellular ves-
sel ghosts. Furthermore, isolectin staining did not reveal
any evidence of filopodia or vascular sprouting during
this phase of vascular alteration, confirming that these
vascular abnormalities do not form by sprouting angio-
genesis but by non-neovascular remodeling.
Consistent with this observation, whole-retina quantita-
tive PCR (qPCR) for VEGF on the RCS rat and RD1 mouse
(at 5 months and 4.5 months of age, respectively) re-
vealed only small changes in transcript expression, rela-
tive to the wild type (Figure 1N). To compare VEGF levels
in the RCS rat and RD1 mouse with a rodent model of
retinal neovascularization, we measured VEGF mRNA ex-
pression in the Vldlr/ mouse.17,23 In this mouse, which
models retinal angiomatous proliferation, there is marked
intraretinal neovascularization commencing from approx-
imately P14 and continuing through to approximately
P30. By 4 months of age, a portion of these abnormalities
appear as plaques containing associated RPE on the
outer retina (Figure 1, L and M).24 We therefore evaluated
whole-retina VEGF transcript expression by qPCR at P21
and observed a substantially greater fold change in
VEGF expression, relative to the RCS rat or RD1 mouse
(Figure 1N). In conjunction with the absence of tip cells,
as judged by a lack of endothelial cell filopodia, these
results suggest that VEGF-induced neovascularization is
unlikely to be a major contributor to the observed remod-
eling of vessels in the RD1 mouse and RCS rat.
Differentially Expressed Genes in Retinal
Microvessels of the RCS Rat and RD1 Mouse
Irrespective of disease causation, we hypothesize that
downstream non-neovascular pathogenic changes are
likely to be mediated by common mechanisms. To gain
insight into the transcriptional programming that drives
such vascular abnormalities, retinal microvessel frag-
ments were purified from the retina of the RCS and RD1
mouse using anti-PECAM-1 magnetic beads (see Sup-
plemental Figure S1A at http://ajp.amjpathol.org). Vessel-
enriched and vessel-depleted fractions were obtained
and examined by phase contrast and epifluorescent mi-
croscopy (see Supplemental Figure S1B http://ajp.
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firmed good vessel recovery and substantial enrichment
of endothelial cell markers (see Supplemental Figure S1,
C and D, at http://ajp.amjpathol.org). To test whether the
vessel-enriched fraction contained other cell types be-
sides endothelial cells, we performed qPCR with primers
for the pericyte marker desmin, the glial marker PDGFR,
and the photoreceptor marker rhodopsin. The resulting
data revealed contamination of glial cells, minor con-
tamination by pericytes, but virtually no contamination
from photoreceptors (see Supplemental Figure S2,
A–C, at http://ajp.amjpathol.org).
Global gene expression analysis was then undertaken
to identify genes in the endothelial-enriched fractions that
may contribute to retinal non-neovascular remodeling in
the RD1 mouse and RCS rat. Microarray analysis fol-
lowed by false discovery rate statistical post hoc test with
an adjusted P value of 0.05 revealed 3270 genes that
were differentially regulated in the RD1 mouse. Reducing
the stringency for the RCS rat by removing the post hoc
test and using a fold change cutoff of 2 and a P value
of 0.01 revealed 341 differentially regulated genes. Of
these, 60 transcripts were common to the RD1 mouse
and the RCS rat (see Supplemental Table S1 at http://
ajp.amjpathol.org). Of the differentially regulated genes,
the small secreted signaling peptide apelin (Apln) and its
receptor (Aplnr), both of which have previously been im-
plicated in vascular development and pathology,25–29
were significantly up-regulated. Also up-regulated were
adrenomedullin (Adm) and plasmalemma vesicle associ-
ated protein (Plvap); these are vascular-associated
genes that have the potential to affect vascular function.
Other genes found to be up-regulated included glial
fibrillary acidic protein (Gfap) and the GABAA receptor
(Gabra1) derived from contaminating astroglia and
neurons, respectively. Notably, the GABAA receptor
has been implicated in vascular remodeling in the
brain.30 However, many of the genes lacked any obvi-
ous functional connection to the vasculature. Further-
more, many of the down-regulated genes most likely
resulted from the loss of contaminating photoreceptorsin the degenerate retinas (ie, phosducin, recoverin,
and retbindin, among others). Because of the increas-
ingly prevalent notion that apelin and its receptor affect
vascular development and pathology, Apln and Aplnr
were chosen for further analysis.
Apelin and Its Receptor Are Up-Regulated in the
Retinal Vasculature of the RCS Rat and RD1
Mouse
The microarray gene expression profiling of the dystro-
phic RCS rat and RD1 mouse retinal vasculature revealed
an increase in the expression of Aplnr by 2.7-fold and
5.7-fold and of Apln by 8.9-fold and 2.9-fold, respectively
(see Supplemental Table S1 at http://ajp.amjpathol.org).
To validate the microarray gene expression data, we
undertook qPCR analysis on RNA isolated from total
mouse and rat retinas. In agreement with the microarray
results, a statistically significant increase in Apln and
Aplnr expression was observed in both animal models
(Figure 2A). To establish whether the observed increase
in retinal Aplnr mRNA in the animal models resulted in an
increase in protein expression, Aplnr levels from whole-
retina lysates of the RCS rat and RD1 mouse were eval-
uated by Western blot analysis. In both animal models,
we detected a significant increase in Aplnr, relative to
control levels (Figure 2, B and C). To determine whether
expression in the retina was restricted to the vasculature
we analyzed by qPCR the vessel-enriched and the ves-
sel-depleted fractions of mouse retinal preparations.
Aplnr expression was restricted to the vessel-enriched
sample, indicating that the receptor is not expressed by
cells of the neural retina. However, although Apln expres-
sion was predominantly vascular, it was also observed in
the vessel-depleted fraction (Figure 2D) suggesting that
other cells, such as Müller glia, are also a potential
source of the ligand. The expression of Aplnr was then
confirmed by immunohistochemistry in the RCS rat, with a
vascular pattern of staining observed in both congenic
Figure 2. Apln and Aplnr are increased in the
RCS and RD1 rodent retina. A: Aplnr and Apln
expression as measured by qPCR in retinal ex-
tracts of RCS dystrophic rats (n  3), relative to
congenic RCS rats (n 3), both 20 weeks of age,
and of RD1 mice (n  3), relative to wild-type
C57BL/6J mice (n  3), both 4.5 months of age.
B: Protein expression of Aplnr in RCS dystrophic
versus nondystrophic rat retina (n  4) and in
RD1 versus C57BL/6J mouse retina (n  4). C:
Representative findings of densitometry per-
formed on three independent Western blots. D:
Vessels were purified from mouse retinas and
the vessel-enriched and vessel-depleted frac-
tions were analyzed for Aplnr and Apln expres-
sion by qPCR. Data are expressed as means 
SEM (n  3). *P  0.05; **P  0.01, Student’s
t-test. E–H: Congenic (E) and dystrophic (F–H)
RCS rat retinas were flat-mounted and immuno-
stained for Aplnr. At higher magnification (H),
Aplnr staining is visible in telangiectatic vessels
(arrowheads). Scale bars: 100 m (E–G);
20 m (H).and dystrophic animals (Figure 2, E–H).
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Developmental Vascular Sprouting but Does
Affect Developmental Vascular Remodeling
Having established that the remodeled pathogenic ves-
sels of the RCS rat and RD1 mouse retina express in-
creased levels of apelin and its receptor, we next inves-
tigated whether loss of apelin affected normal retinal
vascular development and remodeling. As has been pre-
viously reported,31 developmental retinal angiogenesis in
the Apln/ mouse18 is largely unaffected, with only a
small decrease in branching of the deeper plexus beingobserved (P  0.01; Figure 3, A–C). We therefore under-
took a more detailed study of the vascular organization in
these animals. Although whole-mounted retinas at P8 and
P21 from the Apln/ mouse revealed no gross vascular
abnormalities, in the superficial layer the total number of
radial veins and arteries was decreased, relative to
C57BL/6J mice (P  0.05; Figure 3D). Moreover, arterio-
venous crossings were observed with much greater fre-
quency (P  0.01; Figure 3, E and F). On closer exami-
nation, we also found clear evidence of abnormal
remodeling of radial veins in Apln/ mice. In control
Figure 3. Developmental vascular remodeling is compro-
mised in the Apln/ mouse retina. A and B: Deep vascular
plexus from C57BL/6J control and Apln/ mice at P21. C:
Quantification demonstrates reduced vessel branching in the
deep plexus of Apln/ mice at P14 (n  5, control; n  3,
Apln/) and at P21 (n  3). D and F: Quantification of the
average number of radial veins and arteries (D) and arterio-
venous crossings (artery over vein) (F) in Apln/mice (n
32) and C57BL/6J mice (n  25) at ages P8 to P21. Data are
expressed as means  SEM. *P  0.05; **P  0.01, Student’s
t-test. E: Frequent arteriovenous crossings are observed in
the Apln/ mouse. Arrowheads indicate arteriovenous
crossings. A, arteries; V, veins. Inset shows a higher power
magnification of a single arteriovenous crossing. G–L: Re-
modeled vein of C57BL/6J mice (G–I) and Apln/ mice
(J–L) at P21. a, artery; v, vein. G: Phenotype of a radial vein
(arrow) remodeling from the superficial to the deeper
plexus, viewed from the inner retina of C57BL/6J mouse at
P21. H: Higher power magnification of the inner retinal
vascular layer showing remodeled radial vein (arrow). I:
Projected serial Z-stacks (Imaris software version 7.3) of the
same vessel (arrows), shown in the y axis (top panel) and
z axis (bottom panel). J–L: Similar images taken from an
Apln/ mouse, showing termination of the radial vein within
the superficial plexus, where it branches, but is not remodeled
into a deep drainage vein. Arrows indicate the bifurcation
point of the radial vein. M: Quantification of the number of
remodeled radial veins from control C57BL/6J mice and
Apln/mice at P8 to P21. Data are expressed as means SEM
(n  10, control; n  11, Apln/). *P  0.05, Student’s t-test.
N andO: In situ hybridization forAplnr in C57BL/5J mice (P11).
Arrowheads in N indicate the superficial radial vein and the
arrow shows the point at which the radial vein remodels to-
wards the deeper plexus to form a deep drainage venule. The
arrow in O shows the same vein as in N emerging into the
deeper plexus. Arrowheads in O indicate the deep drainage
venule. Scale bars: 100 m (G and J); 50 m (A, B, E, H, K, N,
and O); 20 m (I and L).C57BL/6J mice, veins develop in a strictly alternating
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opment. Subsequently, as the deeper plexus develops,
some (but not all) of the superficial veins are reorganized,
through remodeling of existing vessels, into deeper
plexus drainage veins (Figure 3, G–I; see also Supple-
mental Movies S1 and S2 at http://ajp.amjpathol.org). This
leads to a relocation of veins from the superficial to the
deeper plexus, although not by physical vessel translo-
cation but rather by network remodeling. This remodeling
process was disturbed in Apln/ mice, with most super-
ficial veins remaining at the surface, and with dramat-
ically reduced development of drainage veins in the
deeper plexus (Figure 3, J–L). Quantification of the
number of these remodeled veins per retina revealed a
significant reduction in the Apln/ mice, relative to
control animals (Figure 3M), demonstrating a promi-
nent role for apelin in remodeling the retinal vascular
plexus. To corroborate our findings we conducted in
situ hybridization to detect Aplnr mRNA expression in
retinal flat mounts. A positive signal was observed
in the superficial radial and deep drainage retinal veins
of the wild-type mouse at P11 and in the remodeled
interconnecting vessels linking these two vessels (Fig-
ure 3, N and O).
Apelin Does Not Contribute to the Development
of Choroidal Neovascularization or Pathogenic
Intraretinal Neoangiogenesis
To ascertain whether apelin contributes to pathogenic
neovascularization in the retina, we investigated whether
laser-induced CNV, a feature of wet age-related macular
degeneration, was attenuated in Apln/ mice. CNV wasinduced in Apln/ and in control C57BL/6J mice, and
fluorescein angiography was used to determine the size
and permeability of the neovascular lesion. Neither at the
early phase of fluorescein angiography, which reflects
the size of the neovasculature, nor at the late phase,
which indicates degree of fluorescein leakage, did find-
ings differ between the Apln/ and control mice (Figure
4, A–E). Furthermore, analysis of lesion area (see Sup-
plemental Figure S3 at http://ajp.amjpathol.org) and vol-
ume showed no difference between Apln/ and control
mice (Figure 4, F–H). These data demonstrate that apelin
does not contribute significantly to the size or permeabil-
ity of the CNV lesion.
Because subretinal neoangiogenesis in CNV is de-
rived from the choroid, and not the retina, we next used
the Vldlr/ mouse, which exhibits features of human
retinal angiomatous proliferation, a condition found in a
subset of neovascular age-related macular degenera-
tion patients in which intraretinal neovascularization
originates from the deep vascular plexus and extends
toward the RPE. Apln/ and Vldlr/ mice were
crossed to generate homozygous Vldlr/wild-type Apln
(V//A/) and homozygous knockout Vldlr/homozy-
gous knockout Apln (V//A/) littermates. These off-
spring were then examined for the occurrence of neo-
vascular growths emerging from the deep vascular
plexus at P28 (Figure 4, I and J). The absence of apelin
had no significant effect on the number of neovascular
sprouts, compared with Vldlr/ alone (Figure 4K). As
with the CNV lesions, these observations provide
strong evidence that apelin does not have any signifi-
cant effect in these models of pathogenic neovascu-
Figure 4. Apelin does not contribute to patho-
genic retinal angiogenesis. A–D: Representative
fundus fluorescein angiographs of control
C57BL/6J mice and Apln/ mice at 2 weeks
after laser-induced choroidal neovascularization.
Early (90 seconds) and late (7 minutes) time
points after fluorescein injection correspond to
the size of the neoangiogenic lesion and its per-
meability, respectively. E: Quantification of the
area and permeability of the CNV lesion. Data
are expressed as means SEM (n 3). F and G:
Representative three-dimensional reconstruction
(Imaris software version 7.3) of CNV lesions in
control C57BL/6J mice (F) and in Apln/ mice
(G). H: Quantification of CNV lesion volume.
Data are expressed as means  SEM (n  3). I
and J: Representative images of retinal whole-
mounts stained for vasculature in Vldlr/ mice
(I) and in Vldlr//RD1 double-mutant (R/)
mice (J), showing neovascular sprouts (ar-
rows); inset shows a single neovascular sprout.
K: Quantification of the intraretinal neovascular
sprouts in Vldlr/ retina (n  31) and
Vldlr//RD1 double-mutant (R/) retina (n 
23). Scale bars: 50 m (F, G, I, and J); 20 m (J,
inset).larization in the retina.
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Neovascular Remodeling in the Retina of the
RD1 Mouse
Having established that apelin is not required for patho-
genic neoangiogenesis in the CNV and Vldlr/ animal
models, we next tested whether apelin is involved in non-
neovascular remodeling induced by photoreceptor degen-
eration as described above. Apln/ and RD1 mice were
crossed to generate homozygous RD1 mutant/wild-type
Apln (R//A/), homozygous RD1 mutant/heterozy-
gous Apln (R//A/), or homozygous RD1 mutant/ho-
mozygous knockout Apln (R//A/) littermates. These
progeny were examined for the occurrence of retinal
vascular remodeling at 4.5 months of age. Similar to RD1
mutant animals, all crossed mice underwent thinning of
the neuroretina due to photoreceptor loss (data not
shown). In R//A/ (Figure 5, A and B) and R//A/
animals (Figure 5, E and F), tortuous telangiectatic ves-
sels were apparent throughout the deep vascular net-work, either as part of the capillary network or as vessels
linked to the deep drainage veins, as described above
for the RD1 mouse. In contrast, RD1 animals that lacked
apelin (R//A/) exhibited a marked reduction in tel-
angiectatic vessels (Figure 5, I and J). Most notably, the
tortuous remodeled deep drainage vessels, as described
above, were completely absent (Figure 5M).
Examination of the spatial organization of the superfi-
cial radial veins in the R//A/ mice revealed that they
penetrated the deeper plexus in a fashion identical to that
seen in the RD1 mouse (Figure 5, C and D). R//A/
mice also had remodeled drainage veins (Figure 5, G
and H). Similar to the Apln/ mouse, the R//A/ also
exhibited a dramatic reduction in remodeled drainage
veins (Figure 5, K and L). Loss of these large remodeled
drainage veins may therefore explain the absence of
telangiectatic deep drainage vessels observed in the
R//A/ mice. However, in the R//A/ mouse a
significant number of telangiectatic vessels was ob-
Figure 5. Loss of apelin prevents physiological
radial vein remodeling in the RD1 mouse. Rep-
resentative images of telangiectatic vessels asso-
ciated with a deep drainage vein in an R//
A/ retina at 4.5 months of age (A–D) and in an
R//A/ retina from a littermate at 4.5 months
of age (E–H). Such vascular abnormalities and
drainage veins are absent in an R//A/ ret-
ina from a littermate at 4.5 months of age (I–L).
Retinas were visualized by epifluorescent mi-
croscopy (5 objective) (A, E, and I), by confo-
cal microscopy showing a single section (16
objective) (B, F, and J), or by projection of a
serial Z-stack (Imaris software version 7.3; 40
objective) (C, G, and K), with three-dimensional
reconstructions of the Z-stack projections (D, H,
and L). S, superficial plexus; D, deep plexus.
Images are viewed from the outer retina. A and
E: Arrow indicates the radial vein in the super-
ficial plexus, associated with the telangiectatic
vessels seen at higher magnification in B and F
(arrowheads). B, C, F, and G: Arrows indicate
the emergence of the drainage vein into the
deeper plexus. Arrow in K shows a radial vein
which has not remodelled. M: Quantification of
remodeled radial veins with associated telangi-
ectasis in R//A/, R//A/, and R//
A/ mice at 4.5 months of age (n  10, n  4,
and n  11 retinas, respectively, from five lit-
ters). Data are expressed as means SEM. **P
0.01, Student’s t-test. N–P: Loss of apelin reduces
the tortuosity of abnormal retinal vessels (ar-
rows), independently of deep drainage veins.
Representative images of tortuous vessels in the
R//A/ and R//A/ retinas at 4.5
months of age (N and O), which are reduced in
R//A/ (P). Q: The average number of tor-
tuous vessels exhibiting 360-degree turns in
R//A/, R//A/, and R//A/ mice
(n  10, n  4, and n  11 retinas, respectively;
from five litters). Data are expressed as means
SEM. **P  0.01, Student’s t-test. Scale bars: 100
m (A, E, and I); 50 m (B, F, J, and N–P); 20
m (C, D, G, K, and L); 10 m (H).served in the surviving intermediate/deep capillary
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gated whether depleting apelin reduced the number of
telangiectatic capillaries in this cohort of vessels, be-
cause these telangiectatic capillaries would be indepen-
dent of the loss of deep draining veins. In the R//A/
and R//A/ mice, numerous telangiectatic capillaries
were observed (Figure 5, N and O). In the R//A/
mice, abnormal capillaries were also observed, but these
exhibited reduced and negligible tortuosity, compared
with those seen in the R//A/ mice, respectively (Fig-
ure 5, O and P). When the level of tortuosity was quanti-
fied by enumerating the number of vessels with 360-
degree turns per retina, the degree of telangiectasia in
the R//A/ mice was substantially reduced (Figure
5Q). These data provide strong evidence that apelin reg-
ulates the pathogenic non-neovascular remodeling of mi-
crovessels, particularly with respect to telangiectasia.
Discussion
Gene expression analysis of the vasculature of two ani-
mal models of retinal degeneration with associated vas-
cular remodeling revealed a number of differentially ex-
pressed genes common to both pathologies. Two of
these genes, encoding the small secreted peptide Apln
and its cognate receptor Aplnr, were significantly up-
regulated, relative to control vessels, and were selected
for further investigation. Apelin exists as an inactive 77-
amino-acid preproprotein and as various active cleavage
products, of which apelin-13 is the most biologically ac-
tive. The apelin receptor, for which apelin is the only
known ligand, is a G protein-coupled receptor (GPCR)
that associates with both Gi and Gq heterotrimeric G
proteins to induce activation of Akt/ERK and PLC, re-
spectively.32,33 Current data suggest that the vascular
endothelium is a major target of apelin signaling, with
various downstream effects such as increased cell divi-
sion and migration27,34 and eNOS activation and NO
production.35,36 In addition, apelin has been reported to
modulate developmental angiogenesis,25,26,28,31,34,37
pathogenic angiogenesis,26,29,37,38,39,40,41 and angio-
genesis in in vitro assays.27,34 Although the overall inter-
pretation of many of these studies is that apelin is in-
volved in angiogenesis, close inspection reveals that that
the evidence is far from conclusive. For example, many
studies do not distinguish between sprouting angiogen-
esis and vascular remodeling. Thus, the common read-
outs used to assess angiogenesis, such as vessel den-
sity, branch points and vascular structural abnormalities,
may be altered as result of vascular remodeling alone
(eg, increased or decreased vessel pruning). Moreover,
many studies simply demonstrate a correlation between
Apln/Aplnr expression and angiogenesis but do not dem-
onstrate a causal link and others are based on imperfect
in vitro cell culture models. Similarly, in the clinical setting,
apelin expression is significantly increased in the vitreous
of patients with proliferative diabetic retinopathy,42,43 but
again both neovascularization and vascular remodeling
occur. More consistent with our findings is the observa-
tion that apelin is necessary for normal vessel caliberdevelopment in various tissues.44,45 Nevertheless, as dis-
cussed below, the apelinergic pathway may contribute to
angiogenesis, especially in the context of modifying the
VEGF response.
We observed that Apln and Aplnr are coexpressed in
the retinal microvasculature, implying the presence of
autocrine signaling. Although Aplnr expression in the ret-
ina is restricted to the retinal vessels, demonstrating the
vasculature as the primary target of apelin activity, some
apelin expression was also observed in the nonvascular
compartment. This latter finding may be due to expres-
sion in Müller cells,46 which is pertinent, given that Müller
cell end-feet associate closely with the inner retinal vas-
culature and are likely to play an important part in deter-
mining vascular function. In the vasculature of the RCS
and RD1 rodent models of retinal degeneration, the levels
of apelin and its receptor were significantly up-regulated,
which is consistent with them being under similar regu-
latory control. In many tissues, the expression patterns of
Apln and Aplnr have been shown to be closely aligned,
with Apln and Aplnr gene expression coordinated through
SP1-mediated transcriptional regulation.47,48 Of note, it
has been reported that a single-nucleotide polymorphism
at an SP1 binding site in the 5= flanking region of the Aplnr
gene induces Aplnr activity and confers an increased risk
of cerebral infarct.47 Although the mechanism is currently
unknown, we might speculate that inceased microvascu-
lar tortuosity due to Apln/Aplnr-mediated remodeling may
predispose to increased infarct susceptibility and hem-
orrhage in the brain.
Earlier reports have implicated Apln and Aplnr in reti-
nal blood vessel development31 with enhanced mRNA
expression at the leading edge of the superficial plexus
as it develops toward the periphery.25,28,49 In the Apln/
mouse, however, only minor transient delays in retinal
vascular development have been reported.31 We ob-
served reduced branching of the deeper plexus at P14
and P21 in Apln/ mice, as well as a significant de-
crease in the number of radial arteries and veins and an
increase in the frequency of arteriovenous crossings, rel-
ative to C57BL/6J controls. Most notable, however, was
the novel observation that Apln/ mice have reduced
remodeled radial veins. In control animals, an average of
2.1 radial veins in the superficial plexus remodel and
become integrated into the deeper vascular plexus as it
develops, becoming deep drainage venules.15 The
mechanism through which this occurs is currently un-
clear, but given that the deeper plexus arises from all
radial veins, and not just the subset that remodels down-
ward, it seems likely that this is a regulated process. Our
data, therefore, support our hypothesis that apelin is an
important regulator of this aspect of developmental vas-
cular remodeling. Notably, other deep venules that result
from branching from the radial veins were unaffected by
loss of apelin, because they were present in both
C57BL/6J and Apln/ mice.
Having established that apelin is required for some ele-
ments of developmental vascular remodeling in the retina,
the question arose of whether, as suggested by the gene
expression data, apelin is also required for pathogenic
non-neovascular remodeling. The RD1 mouse is an ani-
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vascular telangiectasia in the absence of any significant
neoangiogenesis. We therefore generated Apln-knockout
mice on the RD1 background to test whether the apelin-
ergic pathway contributes to telangiectatic vascular remod-
eling. These mice exhibited a striking loss of telangiectatic
vessels. Although the loss of some telangiectatic deep
venules may result from the failure to develop remodeled
veins, the number of telangiectatic capillaries not asso-
ciated with these vessels was also reduced substantially.
This provides compelling evidence that apelin is essen-
tial for pathogenic non-neovascular remodeling in the
retina.
Apelin has been implicated in pathogenic neoangio-
genesis.26,27,29,37–41 To gain further insight into the role
of apelin in retinal vascular pathology, we investigated
the role of apelin in the CNV and Vldlr/models of retinal
neovascularization. Surprisingly, we observed no differ-
ence in the extent of CNV in Apln/ mice, relative to
wild-type controls; similarly, in the Apln/Vldlr double-
knockout mice the number of intraretinal neovascular
growths was not significantly different from that observed
in the Vldlr/mice. These data appear to be at odds with
the recently reported effects of apelin in the mouse model
of oxygen-induced ischemic retinopathy. The hypoxia-
induced increase in retinal capillary density is attenuated
at P15 and P17 in Apln-knockout mice.39 However, retinal
capillary density is already reduced in these mice at the
age at which oxygen-induced ischemic retinopathy is
induced31 (our data not shown), making it unclear
whether the effects are due primarily to loss of apelin or to
the underlying delay in retinal vascular development in
these animals. Furthermore, it is important to note that the
effects are not permanent, because vessel density
reaches parity between the wild type and Apln/ by
P84.31 Alternatively, this discrepancy may reveal that, as
is the case with TGF, the outcome of apelin signaling is
extremely dependent on context. It may therefore be
proposed that, in the presence of low VEGF expression
(as in the RD1 mouse retina), the apelinergic pathway
cannot independently promote sprouting angiogenesis
and that its primary role is to drive non-neovascular mod-
ifications. In the presence of significantly elevated VEGF,
however, apelin can either contribute to pathogenic vas-
cular sprouting or have no effect, depending on the rel-
ative contribution of other differentially activated costimu-
latory pathways. This is supported by the finding that
apelin exerts its effect on a corneal angiogenesis assay
primarily through a cooperative process involving VEGF
or FGF2.31 It is entirely feasible, therefore, that in retinal
pathological angiogenesis, in which hypoxia is the pre-
dominant driving factor, both apelin and VEGF combine
to determine the extent of new blood vessel growth,31,45
whereas when additional contributing factors are in-
volved, such as in CNV and in the Vldlr/mouse, the role
of apelin in neovascularization is diminished. Our data,
however, suggest that in the retina apelin is involved
predominantly in developmental and pathogenic non-
neovascular remodeling, because it has a marginal effect
in physiological angiogenesis and no effect on patholog-ical neovascularization observed in laser-induced CNV or
Vldlr/ mice.
Over several decades, a great deal of information has
been gathered describing the factors that regulate de-
velopmental, physiological, and pathological sprouting
angiogenesis. Much less, however, is understood of the
factors that control non-neovascular remodeling, despite
its clear pathogenic importance. With the present study,
we have demonstrated that apelin and its cognate recep-
tor Aplnr are involved in remodeling of the vasculature in
retinal development and disease and in the latter case
may represent a novel target for therapeutic intervention.
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